Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines
“We are excited to receive the grant from GIRF and look forward to broadening our pipeline by developing ELI-007 and ELI-008 to target these key cancer mutations. p53 hotspot mutants and mutant BRAF are examples of public cancer neoantigens shared across many patients and tumor types with limited therapeutic options for providing durable therapeutic benefit,” said Peter DeMuth, Ph.D., Chief Scientific Officer at Elicio. “By targeting vaccine components to the lymph nodes, the AMP strategy is ideally suited to enhance tumor-specific immunity with the potential to eradicate tumors and promote durable patient responses.”
Share:
More News
“We are pleased to evaluate the clinical combination of IDE892 with RG6505 in MTAP-deleted RAS-mutant PDAC,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. “This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high
“In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS
“Non-small cell lung cancer is the most prevalent lung disease with more than 8,000 patients in the U.S. diagnosed each year with KRAS G12D-mutations. Receiving Fast Track designation for VS-7375 reinforces both the significant unmet need and the potential of VS-7375 to improve outcomes for patients with KRAS G12D-mutated lung
“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” said John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, Johnson & Johnson. “We believe the proprietary Firelink™ platform will overcome